Last revised by Dr Daniel MacManus on 13 Aug 2021

Gadoversetamide (also known as OptiMARKTM) is an extracellular intravenous contrast agent used in magnetic resonance imaging.

  • linear, non-ionic molecule 
  • 100% renally excreted
  • T1 relaxivity @ 1.5 T: 4.4-5.0
  • concentration: 0.5 mmol/ml
  • recommended dosage: 0.1 mmol/kg

As an extracellular contrast agent, gadoversetamide can be useful in a wide range of MRI applications, including (but not limited to): hepatic imaging, pelvic imaging, cardiac imaging, brain and spine imaging, and musculoskeletal imaging.


There is an association between the use of gadolinium-based contrast agents (GBCAs) in patients with kidney dysfunction and nephrogenic systemic fibrosis (NSF), a rare, but serious, condition. As a result, the use of three GBCAs; gadoversetamide (OptiMARK®), gadopentetate dimeglumine (Magnevist®) and gadodiamide (Omniscan®) are contraindicated in patients with AKI or with chronic, severe kidney disease 2.

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.